Literature DB >> 25385089

Imaging techniques to evaluate cell therapy in peripheral artery disease: state of the art and clinical trials.

Vincenzo Grimaldi1, Concetta Schiano2, Amelia Casamassimi3, Alberto Zullo4,5, Andrea Soricelli2, Francesco Paolo Mancini4, Claudio Napoli1,2.   

Abstract

Cell-based therapies, as potential approach to cure peripheral artery disease (PAD), have been clinically investigated after promising results in preclinical models. The so far published studies are very heterogeneous, as different cell sources, cell types, amounts of administered cells and delivering strategies have been used. Overall, cell therapies for PAD bring about a general improvement of patient's clinical condition, even though conclusions cannot be established due to the small size and non-randomized design of these trials. In this context, non-invasive imaging techniques, aimed to monitor angiogenesis and neovascularization after cell therapy, will help the follow-up of clinical studies. However, still much work is needed to establish advanced imaging procedure to overcome the limitation of the current techniques and to accumulate more data in large populations of patients. Here, we report the main imaging techniques employed to evaluate the outcome of the different cell-based therapies in PAD. Moreover, we focus on both published and ongoing clinical trials utilizing cell therapy in PAD.
© 2014 Scandinavian Society of Clinical Physiology and Nuclear Medicine. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cell therapy; clinical trials; imaging techniques; peripheral artery disease; regenerative medicine; stem cells

Mesh:

Year:  2014        PMID: 25385089     DOI: 10.1111/cpf.12210

Source DB:  PubMed          Journal:  Clin Physiol Funct Imaging        ISSN: 1475-0961            Impact factor:   2.273


  7 in total

Review 1.  Clinical relevance of epigenetics in the onset and management of type 2 diabetes mellitus.

Authors:  Linda Sommese; Alberto Zullo; Francesco Paolo Mancini; Rossella Fabbricini; Andrea Soricelli; Claudio Napoli
Journal:  Epigenetics       Date:  2017-01-06       Impact factor: 4.528

Review 2.  Potential clinical benefits of cell therapy in coronary heart disease: an update.

Authors:  Vincenzo Grimaldi; Alberto Zullo; Francesco Donatelli; Francesco Paolo Mancini; Francesco Cacciatore; Claudio Napoli
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  Epigenetic Hallmarks of Fetal Early Atherosclerotic Lesions in Humans.

Authors:  Filomena de Nigris; Francesco Cacciatore; Francesco P Mancini; Dino F Vitale; Gelsomina Mansueto; Francesco P D'Armiento; Concetta Schiano; Andrea Soricelli; Claudio Napoli
Journal:  JAMA Cardiol       Date:  2018-12-01       Impact factor: 14.676

Review 4.  Possible Muscle Repair in the Human Cardiovascular System.

Authors:  Linda Sommese; Alberto Zullo; Concetta Schiano; Francesco P Mancini; Claudio Napoli
Journal:  Stem Cell Rev Rep       Date:  2017-04       Impact factor: 5.739

Review 5.  Imaging of small animal peripheral artery disease models: recent advancements and translational potential.

Authors:  Jenny B Lin; Evan H Phillips; Ti'Air E Riggins; Gurneet S Sangha; Sreyashi Chakraborty; Janice Y Lee; Roy J Lycke; Clarissa L Hernandez; Arvin H Soepriatna; Bradford R H Thorne; Alexa A Yrineo; Craig J Goergen
Journal:  Int J Mol Sci       Date:  2015-05-18       Impact factor: 5.923

Review 6.  Sirtuins as Mediator of the Anti-Ageing Effects of Calorie Restriction in Skeletal and Cardiac Muscle.

Authors:  Alberto Zullo; Emanuela Simone; Maddalena Grimaldi; Vincenzina Musto; Francesco Paolo Mancini
Journal:  Int J Mol Sci       Date:  2018-03-21       Impact factor: 5.923

Review 7.  Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human Diseases.

Authors:  Emanuela Stampone; Ilaria Caldarelli; Alberto Zullo; Debora Bencivenga; Francesco Paolo Mancini; Fulvio Della Ragione; Adriana Borriello
Journal:  Int J Mol Sci       Date:  2018-04-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.